BioNTech hopes to launch first anti-cancer drug in 2026

BioNTech hopes to launch first anti-cancer drug in 2026


The German laboratory BioNTech, which has developed one of the innovative vaccines against Covid-19indicated on Wednesday that it was aiming to market a first treatment against cancer in 2026, in particular thanks to messenger RNA (mRNA) technology.

“The company plans to continue developing its projects with a view to its first launch in oncology planned for 2026,” BioNTech said in a press release on the occasion of the publication of its annual results.

BioNTech is currently working on several therapies against different cancers (melanoma, prostate, head and neck, ovarian, lung, colorectal), immunotherapies and vaccines, currently in clinical trials. In total, the laboratory hopes to obtain authorizations for ten of these treatments by 2030, the press release adds.

After selling millions of doses of its anti-Covid vaccine developed with the American giant PfizerBioNTech reinvested its profits in cancer research, the initial specialty of this laboratory created in 2008 by two oncology researchers.

Messenger RNA technology offers new perspectives for the development of innovative therapies against cancer which are the subject of intense competition between several players in the pharmaceutical world.

Moderna is banking on 2025

The American laboratory Modernaone of BioNTech’s rivals, hopes that its therapeutic vaccine against skin cancer, currently in trials, will be approved in 2025.

The therapies these companies are working on aim not to fight cancer cells directly, but to strengthen patients’ immune systems so that they fight cancer.

One of the difficulties is to cope with the “heterogeneity and variability” of cancers, different from one patient to another, by combining “different mechanisms of action”, explains BioNTech. “(…) There are many types of cancer at different stages and the disease differs from one patient to another,” Ugur Sahin, co-founder of BioNTech, explained to the Bild newspaper in November.

Decoding all the possible mutations is a long-term task, making the development of treatments against these diseases more complex than that of the anti-Covid vaccine. “Our goal is to develop a cancer vaccine tailor-made for each patient,” Mr. Sahin told Bild.

After the jump in revenue thanks to sales of the anti-Covid vaccine, the company based in Mainz (west of Germany) saw its turnover return to normal, at 3.8 billion euros per year. last year compared to 17.3 billion in 2022. Annual profit fell to 930 million euros, ten times lower than the previous year.


Source link